Citation: | SHEN Chen, LI Lisha, FU Jianying, XU Ping, LI Juan. Construction and application of standardized non-drug management scheme for progeny patients with degenerative diseases after liver transplantation[J]. Chinese Journal of General Practice, 2024, 22(3): 428-432. doi: 10.16766/j.cnki.issn.1674-4152.003418 |
[1] |
GITTO S, FALCINI M, MARRA F. Metabolic disorders after liver transplantation[J]. Metab Syndr Relat Disord, 2021, 19(2): 65-69. doi: 10.1089/met.2020.0068
|
[2] |
HESSHEIMER A J, RIQUELME F, FUNDORA-SUAREZ Y, et al. Normothermic perfusion and outcomes after liver transplantation[J]. Transplant Rev (Orlando), 2019, 33(4): 200-208. doi: 10.1016/j.trre.2019.06.001
|
[3] |
叶少炜, 钱均霖, 胡泽民. 肝移植后代谢综合征及其防治的研究进展[J]. 岭南现代临床外科, 2022, 22(2): 199-204. doi: 10.3969/j.issn.1009-976X.2022.02.016
|
[4] |
QU W, WEI L, ZHU Z J, et al. Considerations for use of domino cross-auxiliary liver transplantation in metabolic liver diseases: a review of case studies[J]. Transplantation, 2019, 103(9): 1916-1920. doi: 10.1097/TP.0000000000002602
|
[5] |
KOK B, DONG V, KARVELLAS C J. Graft dysfunction and management in liver transplantation[J]. Crit Care Clin, 2019, 35(1): 117-133. doi: 10.1016/j.ccc.2018.08.002
|
[6] |
中国医药生物技术协会慢病管理分会. 肝硬化合并糖尿病患者血糖管理专家共识[J]. 中华糖尿病杂志, 2022, 14(8): 749-763. doi: 10.3760/cma.j.cn115791-20220624-00291
|
[7] |
高血压患者药物治疗管理路径编写委员会. 高血压患者药物治疗管理路径专家共识[J]. 临床药物治疗杂志, 2022, 20(1): 1-24. doi: 10.3969/j.issn.1672-3384.2022.01.001
|
[8] |
中国医师协会器官移植医师分会, 中华医学会器官移植学分会肝移植学组. 中国肝移植受者代谢病管理专家共识(2019版)[J]. 器官移植, 2020, 11(1): 19-29. https://www.cnki.com.cn/Article/CJFDTOTAL-QGYZ202001004.htm
|
[9] |
沃琪, 任咪, 张金彦, 等. 肥胖与肝病: 肝移植的新时代[J]. 肝脏, 2019, 24(11): 1227-1228. doi: 10.3969/j.issn.1008-1704.2019.11.005
|
[10] |
LONARUDO A, MANTOVANI A, PETTA S, et al. Metabolic mechanisms for and treatment of NAFLD or NASH occurring after liver transplantation[J]. Nat Rev Endocrinol, 2022, 18(10): 638-650. doi: 10.1038/s41574-022-00711-5
|
[11] |
PFLUGRAD H, NÖSEL P, DING X, et al. Brain function and metabolism in patients with long-term tacrolimus therapy after kidney transplantation in comparison to patients after liver transplantation[J]. PLoS One, 2020, 15(3): e0229759. DOI: 10.1371/journal.pone.0229759.
|
[12] |
SANADA Y, SAKUMA Y, ONISHII Y, et al. Outcomes after living donor liver transplantation in pediatric patients with inherited metabolic diseases[J]. Ann Transplant, 2021, 26: e932994. DOI: 10.12659/AOT.932994.
|
[13] |
WANG Y J, LI J H, GUAN Y, et al. Diabetes mellitus is a risk factor of acute kidney injury in liver transplantation patients[J]. Hepatobiliary Pancreat Dis Int, 2021, 20(3): 215-221. doi: 10.1016/j.hbpd.2021.02.006
|
[14] |
VAN SON J, STAM S P, GOMES-NETO A W, et al. Post-transplant obesity impacts long-term survival after liver transplantation[J]. Metabolism, 2020, 106: 154204. DOI: 10.1016/j.metabol.2020.154204.
|
[15] |
CZARNECKA K, CZARNECKA P, TRONINA O, et al. Multidirectional facets of obesity management in the metabolic syndrome population after liver transplantation[J]. Immun Inflamm Dis, 2022, 10(1): 3-21. doi: 10.1002/iid3.538
|
[16] |
杨倩, 陈玲, 李亚玲, 等. 肝移植术后代谢综合征预防与管理的证据总结[J]. 中华现代护理杂志, 2022, 28(18): 2424-2430. doi: 10.3760/cma.j.cn115682-20211011-04589
|
[17] |
中国医师协会器官移植医师分会移植免疫学专业委员会, 中国康复医学会器官移植康复专业委员会, 广东省医师协会器官移植医师分会. 慢加急性肝衰竭肝移植围手术期康复评估与干预专家共识[J]. 器官移植, 2022, 13(5): 543-554. doi: 10.3969/j.issn.1674-7445.2022.05.001
|
[18] |
SAKAI T, K0 J S, CROUCH C E, et al. Perioperative management of adult living donor liver transplantation: Part 1 - recipients[J]. Clin Transplant, 2022, 36(6): e14667. DOI: 10.1111/ctr.14667.
|
[19] |
庄莉, 刘相艳. 肝移植受者围手术期管理及并发症预防与治疗[J]. 中华消化外科杂志, 2021, 20(10): 1037-1041. doi: 10.3760/cma.j.cn115610-20210915-00459
|
[20] |
王宇航, 沈振亚. 脂代谢对主动脉疾病发生发展及预后的影响[J]. 中华全科医学, 2023, 21(8): 1374-1378. doi: 10.16766/j.cnki.issn.1674-4152.003126
|